NRX Pharmaceuticals Q4 2025 Earnings Call: Strategic Advancements and Cash Preservation

NRX Pharmaceuticals reported a loss of $16.2 million in 2025, down from $18.5 million in the previous year. The company anticipates drug approval for KETAFREE over the summer and potential approval for NRX-100 within the year. NRX has demonstrated EBITDA positive revenue growth through its HOPE Therapeutics clinics and eliminated all convertible debt from its balance sheet. However, the company still faces risks and uncertainties that could affect its forward-looking statements.